WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Insights
Type
People
Practices
Industries
From Date
To Date
Newsletters

European Antitrust Bimonthly Bulletin – May/June 2026

The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Read More
Newsletters

All Eyes on AI: Regulatory, Litigation, and Transactional Developments – Q1 2026

Wilson Sonsini is pleased to present the next edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the U.S., new EU regulations for AI, international developments, litigation, recent deal highlights, firm publications, and other AI and machine learning highlights.
Read More
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Read More

All Results

Alerts

7.30.26

Delaware Court of Chancery Issues First Decision Addressing Public Benefit Corporations
On July 29, 2026, Vice Chancellor Nathan Cook of the Delaware Court of Chancery issued a decision addressing, for the first time, the fiduciary duties of directors of a public benefit corporation (PBC)—including in a sale of control.1 Under the PBC form, the purpose of corporate decision-making is not merely to advance stockholder value—as is the ultimate purpose of decision-making for a traditional Delaware corporation—but instead to balance three sets of interests: a specific public benefit purpose chosen by the PBC, the best interests of those materially affected by the corporation’s conduct, and stockholders’ pecuniary interests.2 Delaware law first authorized the PBC form in 2013, and since that time, the form has grown in prominence, with many significant public and private companies operating as PBCs. Until this decision, however, there had not yet been direct case law guidance addressing PBCs. The decision, accordingly, is noteworthy for PBCs and companies considering adopting the PBC form.
Alerts

7.30.26

DOJ Revives Targeted Second Requests for Merger Review
On July 23, 2026, the Department of Justice (DOJ) Antitrust Division announced a return to “targeted” Second Request investigations and published a revised model timing agreement. The agreement offers an optional “Expedited Consideration” process potentially allowing investigations to be resolved without a full Second Request production. Under the expedited procedures, parties produce a limited set of documents, data, and information relevant to particular issues and concerns raised by the Antitrust Division. If the targeted production is sufficient to resolve the DOJ’s concerns, the investigation may be terminated without full Second Request compliance. In addition, the targeted production may provide a context for potential settlement negotiations. If concerns remain, the DOJ may require further productions, either of the full Second Request specifications or on modified terms.
Client Highlights

7.30.26

Firm Advises Lead Investor G2 Venture Partners and Eclipse on Antora Energy’s $500 Million Series C
On July 30, 2026, Antora Energy, a leading U.S. energy storage company, announced its closing on $550 million in Series C funding co-led by G2 Venture Partners and Eclipse, with participation from existing and new investors. Wilson Sonsini Goodrich & Rosati advised G2 Venture Partners and Eclipse on the transaction.
Client Highlights

7.30.26

Firm Advises Secturion Systems on Acquisition by Carlyle Group
On July 27, 2026, global investment firm Carlyle announced that it had acquired Secturion Systems, a leading provider of high-speed, NSA-certified hardware encryption solutions that protect sensitive and classified information. The transaction marks the first investment by Carlyle’s dedicated middle-market Aerospace, Defense & Government, and Industrials platform. Wilson Sonsini Goodrich & Rosati advised Secturion on the transaction.
Client Highlights

7.30.26

Wilson Sonsini Advises Dili on $15 Million Series A Led by Khosla Ventures
On July 30, 2026, Dili, an AI compliance company, announced it has raised $15 million in Series A funding. The round was led by Khosla Ventures, with participation from Allianz, Rebel Fund, Brick and Mortar Ventures' Darren Bechtel, and Y Combinator's Garry Tan. Wilson Sonsini Goodrich & Rosati advised Dili on the transaction.
Alerts

7.29.26

Back-to-Back Executive Orders Shape the U.S. Quantum Agenda: What Founders and Investors Need to Know
On June 22, 2026, the administration issued two Executive Orders: Executive Order 14413, Ushering in the Next Frontier of Quantum Innovation (Quantum Innovation Executive Order) and Executive Order 14412, Securing the Nation Against Advanced Cryptographic Attacks (Post-Quantum Cryptography Executive Order). Together, the Executive Orders reinforce the federal government’s long-term commitment to quantum information science and technology (QIST) while continuing to frame quantum as both an economic and national security priority. Although they impose relatively few immediate legal obligations on most companies, the Executive Orders provide important signals about where federal investment, procurement, and strategic partnerships are likely to emerge over the coming years.
Newsletters

7.29.26

European Antitrust Bimonthly Bulletin – May/June 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
News Articles

7.29.26

Weiheng Chen Named Finalist for 2026 ALB Hong Kong Law Awards
Asian Legal Business announced the finalists for its 25th annual ALB Hong Kong Law Awards, which honor outstanding achievements in the legal field, celebrating the exceptional performance of both private practitioners and in-house counsel in Hong Kong. Head of Wilson Sonsini’s Greater China practice Weiheng Chen has been named a finalist in the “Dealmaker of the Year” category. Weiheng has represented clients in many of the largest and most significant M&A and capital markets deals in a variety of industries.
Client Highlights

7.29.26

Wilson Sonsini Advises DroneDeploy on $845 Million Acquisition by Procore Technologies
On July 29, 2026, Procore Technologies, a global provider of construction management software, announced it has entered into a definitive agreement to acquire DroneDeploy, a robotics and visual intelligence platform. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments. Wilson Sonsini Goodrich & Rosati is advising DroneDeploy on the transaction
Press Releases

7.29.26

Wilson Sonsini Appoints Rezwan Pavri as Chair
PALO ALTO, Calif., July 29, 2026 — Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to innovative and growth enterprises worldwide, today announced the appointment of Rezwan Pavri as chair of the firm. A member of the firm’s board of directors and head of its Capital Markets practice, Pavri assumes the role as Wilson Sonsini positions itself for its next phase of growth.
News Articles

7.28.26

Billboard Names Gary Greenstein a Top Music Lawyer for the 10th Consecutive Year
Billboard has named Wilson Sonsini partner Gary Greenstein to its 2026 "Top Music Lawyers" list, an annual recognition honoring the music industry's leading attorneys across areas including talent representation, copyright, licensing, music publishing, streaming, transactions, and litigation. This recognition marks the 10th consecutive year Gary has been named to the prestigious list.
Alerts

7.28.26

FDA Announces Funding Opportunity for Research on Digital Health Technologies in Drug and Biologic Development
Key Takeaways
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.